Biomarkers for atypical Parkinsonism: Some progress, but much work remains

In this issue of Parkinsonism and Related Disorders, two studies address the role of biomarkers for atypical parkinsonian syndromes. Interest in testing experimental treatments for disorders like Multiple Systems Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) has increased recently [1,2], both to meet the needs of patients with these disorders and because they can be thought of as model systems for more common conditions, like Alzheimer's disease. Understanding how to use biomarkers for atypical parkinsonian syndromes is a crucial step in this process.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Editorial Source Type: research